PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Phase 3

Completed

Conditions: Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

Interventions: Drug: Placebo
Drug: PF-04965842 200 mg
Drug: PF-04965842 100 mg

First Posted Date: 2018-08-13

Last Posted Date: 2021-09-20

Lead Sponsor: Pfizer

Target Recruit Count: 1235

Registration Number: NCT03627767

Locations: 🇺🇸
Owensboro Dermatology Associates, Owensboro, Kentucky, United States
🇺🇸
MediSearch Clinical Trials, Saint Joseph, Missouri, United States
🇺🇸
The University of Texas Health Science Center Houston, Houston, Texas, United States

and more 232 locations

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Glasdegib 100 mg single oral dose

First Posted Date: 2018-08-13

Last Posted Date: 2019-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT03627754

Locations: 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Fluconazole 150mg Capsule Originator
Drug: Fluconazole 150mg Capsule Localized Originator

First Posted Date: 2018-08-08

Last Posted Date: 2021-07-16

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03621072

Locations: 🇨🇳
Wuxi People's Hospital//Phase One Unit, Wuxi, Jiangsu, China

A Study of Benzathine Benzylpenicillin Intramuscular Injection in Japanese Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: penicillin G benzathine

First Posted Date: 2018-08-02

Last Posted Date: 2018-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT03612557

Locations: 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

Phase 1

Completed

Conditions: Healthy Females

Interventions: Drug: PF-06651600
Drug: Ethinyl estradiol (EE) and levonogestrel (LN)

First Posted Date: 2018-07-31

Last Posted Date: 2019-04-09

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03608241

Locations: 🇺🇸
Quotient Sciences-Miami, Inc., Miami, Florida, United States
🇺🇸
Quotient Sciences, Coral Gables, Florida, United States

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-06946860
Other: Placebo

First Posted Date: 2018-07-26

Last Posted Date: 2019-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 63

Registration Number: NCT03599063

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Glasdegib Renal Impairment Study

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
Drug: Glasdegib single 100 mg dose in normal healthy subjects

First Posted Date: 2018-07-24

Last Posted Date: 2019-08-29

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03596567

Locations: 🇺🇸
Prism Clinical Research LLC, Saint Paul, Minnesota, United States
🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05221304
Drug: Placebo

First Posted Date: 2018-07-24

Last Posted Date: 2018-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT03597217

Locations: 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Metformin
Drug: PF-06865571

First Posted Date: 2018-07-20

Last Posted Date: 2019-03-28

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03593707

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Phase 3

Active, not recruiting

Conditions: Hemophilia B
Hemophilia A

Interventions: Drug: Standard of Care FIX Replacement therapy
Drug: Standard of Care FVIII Replacement therapy

First Posted Date: 2018-07-16

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 213

Registration Number: NCT03587116

Locations: 🇺🇸
Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, United States
🇺🇸
Penn Blood Disorder Center, Philadelphia, Pennsylvania, United States

and more 77 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy